Mutations in the PIK3CA gene that lead to elevated production of the PI3Ka protein are among the most frequent alterations found in cancer, including in approximately 40% of hormone receptor–positive breast cancers.
Nov 2, 2023
0
0
Metabolites called nucleotides are the building blocks of DNA and can impact cancer's sensitivity or resistance to chemotherapy and radiation in brain cancer. Findings from researchers at the University of Michigan Health ...
Nov 2, 2023
0
29
Imagine the body's cells are well-behaved students in the classroom. The "teachers" are tumor suppressor genes, and they make sure cells follow the rules. But when tumor suppressor genes are away, cells may go astray.
Nov 1, 2023
0
43
Researchers from The Hospital for Sick Children (SickKids), the Ontario Institute for Cancer Research (OICR) and University Health Network (UHN) have demonstrated that by analyzing patients' blood samples, they are able to ...
Oct 24, 2023
0
0
Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of which is guided by biomarker testing.
Oct 18, 2023
0
0
Cancer research has long focused on targeting the genetic mutations that drive tumors. Many of these genetic changes affect genes that allow mutated cells to replicate out of control. While developing drugs to target these ...
Oct 16, 2023
0
20
Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies. But ...
Oct 5, 2023
0
20
Researchers at Vanderbilt-Ingram Cancer Center have discovered a drug target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Oct 4, 2023
0
1
Researchers at VHIO, led by Dr. Cristina Saura, head of the VHIO Breast Cancer Group and the Breast Unit at Vall d'Hebron University Hospital, and Dr. Ana Vivancos, head of VHIO's Genomics laboratory, has shown for the first ...
Sep 14, 2023
0
12
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Sep 14, 2023
0
66
